Structure Therapeutics (NASDAQ:GPCR) Trading Down 4% - Should You Sell?

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report)'s stock price fell 4% during trading on Thursday . The stock traded as low as $20.88 and last traded at $20.92. 146,742 shares traded hands during trading, a decline of 83% from the average session volume of 843,992 shares. The stock had previously closed at $21.79.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on GPCR shares. Cantor Fitzgerald reissued an "overweight" rating and set a $65.00 price objective on shares of Structure Therapeutics in a report on Monday, June 23rd. HC Wainwright dropped their price target on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a research note on Monday, May 12th. JMP Securities reissued a "market outperform" rating and issued a $89.00 price objective on shares of Structure Therapeutics in a report on Monday, June 23rd. Finally, Citigroup began coverage on Structure Therapeutics in a report on Friday, May 2nd. They set a "buy" rating and a $60.00 target price for the company. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics has a consensus rating of "Buy" and an average price target of $76.17.

Structure Therapeutics Price Performance

The firm's fifty day simple moving average is $23.43 and its 200 day simple moving average is $23.72. The company has a market capitalization of $1.21 billion, a PE ratio of -24.23 and a beta of -1.87.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.03). On average, equities research analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current fiscal year.

Institutional Trading of Structure Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Zimmer Partners LP grew its stake in Structure Therapeutics by 77.1% in the 1st quarter. Zimmer Partners LP now owns 100,776 shares of the company's stock valued at $1,744,000 after acquiring an additional 43,876 shares during the period. Vestal Point Capital LP lifted its holdings in Structure Therapeutics by 3.7% during the first quarter. Vestal Point Capital LP now owns 1,788,990 shares of the company's stock valued at $30,967,000 after purchasing an additional 63,990 shares in the last quarter. Cubist Systematic Strategies LLC lifted its holdings in Structure Therapeutics by 3,326.0% during the first quarter. Cubist Systematic Strategies LLC now owns 54,816 shares of the company's stock valued at $949,000 after purchasing an additional 53,216 shares in the last quarter. Point72 Europe London LLP grew its holdings in shares of Structure Therapeutics by 188.7% during the first quarter. Point72 Europe London LLP now owns 90,697 shares of the company's stock worth $1,570,000 after buying an additional 59,277 shares in the last quarter. Finally, DAFNA Capital Management LLC raised its position in shares of Structure Therapeutics by 66.2% in the first quarter. DAFNA Capital Management LLC now owns 59,000 shares of the company's stock valued at $1,021,000 after buying an additional 23,500 shares during the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.